Published in Curr Gastroenterol Rep on May 01, 2013
Esophageal cancer: Recent advances in screening, targeted therapy, and management. J Carcinog (2014) 1.02
State-of-the-art molecular imaging in esophageal cancer management: implications for diagnosis, prognosis, and treatment. J Gastrointest Oncol (2015) 0.80
Application of confocal laser endomicroscopy in the diagnosis and management of Barrett's esophagus. Ann Gastroenterol (2014) 0.78
Gastrointestinal morbidity in obesity. Ann N Y Acad Sci (2014) 0.77
Barrett esophagus: history, definition and etiopathogeny. J Med Life (2014) 0.75
Screening and Preventive Strategies in Esophagogastric Cancer. Surg Oncol Clin N Am (2017) 0.75
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
Incidence of adenocarcinoma among patients with Barrett's esophagus. N Engl J Med (2011) 8.62
American Gastroenterological Association medical position statement on the management of Barrett's esophagus. Gastroenterology (2011) 5.93
Comparison between endoscopic and surgical resection of mucosal esophageal adenocarcinoma in Barrett's esophagus at two high-volume centers. Ann Surg (2011) 4.80
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ (2010) 3.44
Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy (2010) 3.12
Real-time increased detection of neoplastic tissue in Barrett's esophagus with probe-based confocal laser endomicroscopy: final results of an international multicenter, prospective, randomized, controlled trial. Gastrointest Endosc (2011) 2.51
Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc (2010) 2.28
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17
Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell (2012) 2.16
Gastroesophageal reflux might cause esophagitis through a cytokine-mediated mechanism rather than caustic acid injury. Gastroenterology (2009) 2.05
Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology (2002) 2.01
Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut (2002) 1.92
Learning to perform endoscopic resection of esophageal neoplasia is associated with significant complications even within a structured training program. Endoscopy (2011) 1.82
The role of adiponectin in cancer: a review of current evidence. Endocr Rev (2012) 1.78
Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther (2011) 1.77
EMR for Barrett's esophagus-related superficial neoplasms offers better diagnostic reproducibility than mucosal biopsy. Gastrointest Endosc (2007) 1.70
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res (2009) 1.65
Randomized crossover study comparing efficacy of transnasal endoscopy with that of standard endoscopy to detect Barrett's esophagus. Gastrointest Endosc (2012) 1.53
Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology (2010) 1.47
Feasibility, safety, acceptability, and yield of office-based, screening transnasal esophagoscopy (with video). Gastrointest Endosc (2012) 1.46
Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus. Gastroenterology (2012) 1.37
Safety, tolerability, and efficacy of endoscopic low-pressure liquid nitrogen spray cryotherapy in the esophagus. Dis Esophagus (2009) 1.32
Cigarette smoking increases risk of Barrett's esophagus: an analysis of the Barrett's and Esophageal Adenocarcinoma Consortium. Gastroenterology (2012) 1.28
Safety of prior endoscopic mucosal resection in patients receiving radiofrequency ablation of Barrett's esophagus. Clin Gastroenterol Hepatol (2011) 1.22
Associations between adipokines and obesity-related cancer. Front Biosci (Landmark Ed) (2011) 1.19
Deoxycholic acid causes DNA damage while inducing apoptotic resistance through NF-κB activation in benign Barrett's epithelial cells. Am J Physiol Gastrointest Liver Physiol (2011) 1.17
Influence of malpractice history on the practice of screening and surveillance for Barrett's esophagus. Am J Gastroenterol (2007) 1.16
Tobacco smoking increases the risk of high-grade dysplasia and cancer among patients with Barrett's esophagus. Gastroenterology (2011) 1.14
Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus. Gastroenterology (2012) 1.13
Safety and efficacy of multiband mucosectomy in 1060 resections in Barrett's esophagus. Endoscopy (2011) 1.09
Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis Esophagus (2008) 1.07
Surveillance history of endoscopically treated patients with early Barrett's neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus (2008) 1.03
Y chromosome structural and functional changes in human malignant diseases. Mutat Res (2009) 1.02
Associations between leptin and adiponectin receptor upregulation, visceral obesity and tumour stage in oesophageal and junctional adenocarcinoma. Br J Surg (2010) 0.99
Pathophysiology of gastroesophageal reflux disease. J Clin Gastroenterol (2008) 0.98
Is endoscopic surveillance for non-dysplastic Barrett's esophagus cost-effective? Review of economic evaluations. J Gastroenterol Hepatol (2011) 0.96
Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. Stem Cells Dev (2010) 0.94
Selenium, selenoenzymes, oxidative stress and risk of neoplastic progression from Barrett's esophagus: results from biomarkers and genetic variants. PLoS One (2012) 0.94
Bile acids are multifunctional modulators of the Barrett's carcinogenesis. J Physiol Pharmacol (2010) 0.89
Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer (2008) 0.86
Frequency of the mitochondrial DNA 4977bp deletion in oesophageal mucosa during the progression of Barrett's oesophagus. Eur J Cancer (2009) 0.84
Frequent occurrence of mitochondrial DNA mutations in Barrett's metaplasia without the presence of dysplasia. PLoS One (2012) 0.81
Smoking and Barrett's esophagus in women who undergo upper endoscopy. Dig Dis Sci (2011) 0.80
A case of mediastinitis after radiofrequency ablation for Barrett's esophagus. Gastrointest Endosc (2011) 0.79
The resistance of esophageal adenocarcinoma to bile salt insult is associated with manganese superoxide dismutase expression. J Surg Res (2010) 0.79
The role of nitric oxide in the induction of caudal-type homeobox 2 through epidermal growth factor receptor in the development of Barrett's esophagus. Scand J Gastroenterol (2012) 0.79
Endoscopic vs surgical resection for Barrett's intramucosal adenocarcinoma: beyond a therapeutic equipoise. Gastroenterology (2012) 0.77
Endoscopy: NBI in Barrett esophagus--look more and sample less. Nat Rev Gastroenterol Hepatol (2012) 0.77
Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med (2009) 10.91
Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. Gastrointest Endosc (2005) 4.78
Balloon-based, circumferential, endoscopic radiofrequency ablation of Barrett's esophagus: 1-year follow-up of 100 patients. Gastrointest Endosc (2007) 3.53
Durability of radiofrequency ablation in Barrett's esophagus with dysplasia. Gastroenterology (2011) 3.44
Five-year efficacy and safety of photodynamic therapy with Photofrin in Barrett's high-grade dysplasia. Gastrointest Endosc (2007) 3.23
Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology (2002) 2.88
Long-term survival following endoscopic and surgical treatment of high-grade dysplasia in Barrett's esophagus. Gastroenterology (2007) 2.86
Endoscopic ablation of Barrett's esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc (2008) 2.51
Safety and efficacy of endoscopic spray cryotherapy for Barrett's esophagus with high-grade dysplasia. Gastrointest Endosc (2010) 2.28
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward. Clin Cancer Res (2006) 2.24
The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J Natl Cancer Inst (2002) 2.13
Genetic variations in microRNA-related genes are novel susceptibility loci for esophageal cancer risk. Cancer Prev Res (Phila) (2008) 2.11
Meta-analysis of randomized trials comparing the patency of covered and uncovered self-expandable metal stents for palliation of distal malignant bile duct obstruction. Gastrointest Endosc (2011) 2.09
Predictors of stricture formation after photodynamic therapy for high-grade dysplasia in Barrett's esophagus. Gastrointest Endosc (2007) 2.06
History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology (2010) 2.05
The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell (2012) 2.02
Recurrence of esophageal intestinal metaplasia after endoscopic mucosal resection and radiofrequency ablation of Barrett's esophagus: results from a US Multicenter Consortium. Gastroenterology (2013) 1.92
Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology (2009) 1.88
Utility of biomarkers in prediction of response to ablative therapy in Barrett's esophagus. Gastroenterology (2008) 1.87
Age-related changes in the pancreas identified by EUS: a prospective evaluation. Gastrointest Endosc (2005) 1.86
Combined endoscopic mucosal resection and photodynamic therapy versus esophagectomy for management of early adenocarcinoma in Barrett's esophagus. Clin Gastroenterol Hepatol (2003) 1.82
Overutilization of endoscopic surveillance in nondysplastic Barrett's esophagus: a multicenter study. Gastrointest Endosc (2011) 1.82
Depth of submucosal invasion does not predict lymph node metastasis and survival of patients with esophageal carcinoma. Clin Gastroenterol Hepatol (2009) 1.74
Prevalence and predictors of recurrent neoplasia after ablation of Barrett's esophagus. Gastrointest Endosc (2009) 1.66
A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res (2009) 1.65
Initial evaluation of the efficacy and safety of endoscopic ultrasound-guided direct Ganglia neurolysis and block. Am J Gastroenterol (2007) 1.58
Prospective assessment of EUS criteria for lymphadenopathy associated with rectal cancer. Gastrointest Endosc (2008) 1.55
Endoscopic tri-modal imaging is more effective than standard endoscopy in identifying early-stage neoplasia in Barrett's esophagus. Gastroenterology (2010) 1.47
Biomarkers in gastrointestinal cancers. Am J Gastroenterol (2008) 1.45
Comparison of methods to detect neoplasia in patients undergoing endoscopic ultrasound-guided fine-needle aspiration. Gastroenterology (2012) 1.43
MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin Cancer Res (2009) 1.35
Predictors of progression in Barrett's esophagus: current knowledge and future directions. Am J Gastroenterol (2010) 1.35
Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology (2007) 1.34
Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One (2010) 1.33
Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a population-based study. Am J Gastroenterol (2011) 1.32
Prevalence of overweight misperception and weight control behaviors among normal weight adolescents in the United States. ScientificWorldJournal (2006) 1.28
Utility of endoscopic ultrasound in the diagnosis of aberrant right subclavian artery. J Gastroenterol Hepatol (2007) 1.27
The American Society for Gastrointestinal Endoscopy PIVI (Preservation and Incorporation of Valuable Endoscopic Innovations) on imaging in Barrett's Esophagus. Gastrointest Endosc (2012) 1.23
Safety of prior endoscopic mucosal resection in patients receiving radiofrequency ablation of Barrett's esophagus. Clin Gastroenterol Hepatol (2011) 1.22
Significance of neoplastic involvement of margins obtained by endoscopic mucosal resection in Barrett's esophagus. Am J Gastroenterol (2007) 1.20
MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev Res (Phila) (2013) 1.18
EUS-FNA assessment of extramesenteric lymph node status in primary rectal cancer. Gastrointest Endosc (2011) 1.17
Endoscopic ultrasound-guided trucut biopsy of the cyst wall for diagnosing cystic pancreatic tumors. Clin Gastroenterol Hepatol (2005) 1.16
Bile acid exposure up-regulates tuberous sclerosis complex 1/mammalian target of rapamycin pathway in Barrett's-associated esophageal adenocarcinoma. Cancer Res (2008) 1.15
Genome-wide catalogue of chromosomal aberrations in barrett's esophagus and esophageal adenocarcinoma: a high-density single nucleotide polymorphism array analysis. Cancer Prev Res (Phila) (2010) 1.12
A comparison of conventional cytology, DNA ploidy analysis, and fluorescence in situ hybridization for the detection of dysplasia and adenocarcinoma in patients with Barrett's esophagus. Hum Pathol (2008) 1.12
Frozen section analysis of esophageal endoscopic mucosal resection specimens in the real-time management of Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 1.12
Three-tiered risk stratification model to predict progression in Barrett's esophagus using epigenetic and clinical features. PLoS One (2008) 1.12
Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma. J Gastroenterol Hepatol (2005) 1.10
The development of a fluorescence in situ hybridization assay for the detection of dysplasia and adenocarcinoma in Barrett's esophagus. J Mol Diagn (2006) 1.09
False positive endoscopic ultrasound fine needle aspiration cytology: incidence and risk factors. Gut (2010) 1.09
Gains and amplifications of c-myc, EGFR, and 20.q13 loci in the no dysplasia-dysplasia-adenocarcinoma sequence of Barrett's esophagus. Cancer Epidemiol Biomarkers Prev (2008) 1.08
Diagnostic performance of two confocal endomicroscopy systems in detecting Barrett's dysplasia: a pilot study using a novel bioprobe in ex vivo tissue. Gastrointest Endosc (2012) 1.08
EMR for early stage esophageal cancer: setting the stage for improved patient outcomes. Gastrointest Endosc (2003) 1.07
Biopsy depth after radiofrequency ablation of dysplastic Barrett's esophagus. Gastrointest Endosc (2010) 1.03
Distinct role of Kruppel-like factor 11 in the regulation of prostaglandin E2 biosynthesis. J Biol Chem (2010) 1.02
Muscularis mucosae duplication and the musculo-fibrous anomaly in endoscopic mucosal resections for barrett esophagus: implications for staging of adenocarcinoma. Am J Surg Pathol (2008) 1.00
Metabolic syndrome as a risk factor for Barrett esophagus: a population-based case-control study. Mayo Clin Proc (2013) 0.99
Adequacy of endoscopic ultrasound core needle biopsy specimen of nonmalignant hepatic parenchymal disease. Clin Gastroenterol Hepatol (2008) 0.98
Successful endoscopic treatment of intraductal extension of a villous adenoma with high-grade dysplasia, with 3-year follow-up. Gastrointest Endosc (2011) 0.96
A comparative analysis by SAGE of gene expression profiles of Barrett's esophagus, normal squamous esophagus, and gastric cardia. Gastroenterology (2005) 0.96
Squamous overgrowth is not a safety concern for photodynamic therapy for Barrett's esophagus with high-grade dysplasia. Gastroenterology (2008) 0.95
Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer (2007) 0.94
Barrett esophagus: an update. Nat Rev Gastroenterol Hepatol (2010) 0.92
Secondary linitis plastica of the rectum: EUS features and tissue diagnosis (with video). Gastrointest Endosc (2008) 0.92
Mechanisms of disease: Carcinogenesis in Barrett's esophagus. Nat Clin Pract Gastroenterol Hepatol (2004) 0.91
Isolation and sequencing of a novel tropomyosin isoform preferentially associated with colon cancer. Gastroenterology (2002) 0.91
Photodynamic therapy for unresectable cholangiocarcinoma: a comparative effectiveness systematic review and meta-analyses. Photodiagnosis Photodyn Ther (2012) 0.89
Prospective cytological assessment of gastrointestinal luminal fluid acquired during EUS: a potential source of false-positive FNA and needle tract seeding. Am J Gastroenterol (2010) 0.89
Factors associated with increased survival after photodynamic therapy for cholangiocarcinoma. Clin Gastroenterol Hepatol (2007) 0.88
Prospective study of bacteremia and complications With EUS FNA of rectal and perirectal lesions. Clin Gastroenterol Hepatol (2007) 0.88
Endoscopic mucosal resection in the management of esophageal neoplasia: current status and future directions. Clin Gastroenterol Hepatol (2010) 0.87
Fluorescence in situ hybridization mapping of esophagectomy specimens from patients with Barrett's esophagus with high-grade dysplasia or adenocarcinoma. Hum Pathol (2011) 0.86
Epithelial mesenchymal transition and cancer stem cells in esophageal adenocarcinoma originating from Barrett's esophagus. Oncol Lett (2012) 0.86
Preoperative diagnosis of extrapancreatic neural invasion in pancreatic cancer. Clin Gastroenterol Hepatol (2006) 0.86
Correlation of histology with biomarker status after photodynamic therapy in Barrett esophagus. Cancer (2008) 0.86
Safety of endoscopic mucosal resection for Barrett's esophagus. Am J Gastroenterol (2013) 0.85
Population screening for barrett esophagus: a prospective randomized pilot study. Mayo Clin Proc (2011) 0.85
Inhibition of Notch signaling enhances transdifferentiation of the esophageal squamous epithelium towards a Barrett's-like metaplasia via KLF4. Cell Cycle (2014) 0.83
Genome-wide methylation analysis shows similar patterns in Barrett's esophagus and esophageal adenocarcinoma. Carcinogenesis (2013) 0.83
Outcomes of T1b esophageal adenocarcinoma patients. Gastrointest Endosc (2011) 0.82
Preliminary experience comparing routine cytology results with the composite results of digital image analysis and fluorescence in situ hybridization in patients undergoing EUS-guided FNA. Gastrointest Endosc (2007) 0.82
Genetic and epigenetic abnormalities in primary sclerosing cholangitis-associated cholangiocarcinoma. Inflamm Bowel Dis (2013) 0.82
Utility of baseline positron emission tomography with computed tomography for predicting endoscopic resectability and survival outcomes in patients with early esophageal adenocarcinoma. J Gastroenterol Hepatol (2013) 0.81
Prevalence of esophageal eosinophils in patients with Barrett's esophagus. Am J Gastroenterol (2011) 0.80
Endocytoscopy in esophageal cancer. Gastrointest Endosc Clin N Am (2009) 0.80
Allelic imbalance of 7q32.3-q36.1 during tumorigenesis in Barrett's esophagus. Cancer Res (2002) 0.80
Endoscopic therapy for Barrett's esophagus and early esophageal adenocarcinoma. Gastroenterol Clin North Am (2013) 0.79
Local recurrence detection following transanal excision facilitated by EUS-FNA. Hepatogastroenterology (2012) 0.79
Role of mucosal ablative therapy in the treatment of the columnar-lined esophagus. Chest Surg Clin N Am (2002) 0.79
Ablation is in the eye of the beholder. Clin Gastroenterol Hepatol (2013) 0.79
Screening, surveillance, and prevention for esophageal cancer. Gastroenterol Clin North Am (2009) 0.79
A new era: endoscopic tissue transplantation. Curr Opin Gastroenterol (2013) 0.77